Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | Do not list | Complete | ||
| Myfortic | Mycophenolate sodium | Organ rejection in allogeneic renal transplants, Prophylaxis | List in a similar manner to other drugs in class | Complete | ||
| Xolair | Omalizumab | Asthma, severe persistent | Cancelled | |||
| Lyrica | Pregabalin | Pain, Neuropathic | Do not list | Complete | ||
| Tarceva | Erlotinib | Cancer, Lung , non-small cell | List with clinical criteria and/or conditions | Complete | ||
| Kivexa | Abacavir/lamivudine | HIV infection | List in a similar manner to other drugs in class | Complete | ||
| Cipralex | Escitalopram oxalate | Depression, Major Depressive Disorder (MDD) | Withdrawn | |||
| Viread | Tenofovir disoproxil fumarate | HIV infection | List with clinical criteria and/or conditions | Complete | ||
| NovoMix 30 | Insulin aspart/insulin aspart protamine | Diabetes mellitus | Do not list | Complete | ||
| Xolair | Omalizumab | Asthma, severe persistent | Do not list | Complete |
Last Updated : April 27, 2024